Gubra

107,98DKK +1,87 %

HC Andersen Capital saa maksun yhtiöltä Gubra DigitalIR/Corporate Visibility -sopimuksesta. Katso vastuuvapauslauseke.

3 sijoittajaa seuraa yhtiötä

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.

Liikevaihto
199,38 milj.
EBIT %
−0,65 %
P/E -luku
3,31
Osinkotuotto %
-
Tavoitehinta
-
Suositus
-
Päivitetty
-
NASDAQ Copenhagen
GUBRA
Päivän matalin / päivän korkein hinta
107,98 / 109,98 DKK
Markkina-arvo
1,77 mrd. DKK
Vaihto
21,08 t. DKK
Vaihtomäärä, kappaletta
195
Publisher
Gubra (One-pager): Unique high margin CRO business and a strong obesity portfolio in D&P

Learn more about Gubra's uniques high margin CRO business and the strong obesity pipeline in D&P.

Inderes analyysi08.09.2023 - Henrik Ekman, Philip Coombes, Claus Thestrup
Publisher
Life Science Seminar – Wrap up from our event last week – Thursday the 31st. of August.

Life Science Seminar – Wrap up from our event last week – Thursday the 31st. of August.

Analyytikon kommentti05.09.2023 - Henrik Ekman, Claus Thestrup
Publisher
Gubra - Wrap up - H1-2023 interview med CEO Henrik Blou og CFO Kristian Borbos

Gubra - Wrap up - H1-2023 interview med CEO Henrik Blou og CFO Kristian Borbos

Analyytikon kommentti29.08.2023 - Claus Thestrup
Publisher
Gubra – Presentation of Q2 report 2023

Meet and ask questions to Gubra’s CEO Henrik Blou and CFO Kristian Borbos on 28 August at 10.00 am CEST when they present the Q2 report 2023 and the latest development. Gubra has two divisions CRO and D&P, and late in the quarter the company acquired a research service provider MiniGut ApS to the CRO division.

Webcast28.08.2023
Publisher
Gubra stopper samarbejde med Bayer AG.

Gubra stopper samarbejde med Bayer AG.

Analyytikon kommentti25.08.2023 - Henrik Ekman, Claus Thestrup
Publisher
Gubra: Peer nyheder på vægttabsmedicin

I relation til Gubra er der peer nyheder ude på vægttabsmedicin.

Analyytikon kommentti09.08.2023 - Claus Thestrup, Henrik Ekman
Publisher
Introduction to Gubra

Introduction to Gubra - CEO Henrik Blou and CFO Kristian Borbos presenting the company

Analyytikon kommentti14.06.2023 - Claus Thestrup
Publisher
Gubra – Company Introduction

Meet and ask questions directly to Gubra CEO Henrik Blou and CFO Kristian Borbos when they give an introduction to the company and investment case on 13 June at 10.00 am CEST. Gubra is a new company in the HCA space and we look forward to learning more about the investment case.

Webcast13.06.2023